Alan Klotz, Ph.D.Research Fellow, Pharmaceutical and Vaccine Science & Technology at Elanco Animal Health
Dr. Alan V. Klotz is a Research Fellow in Pharmaceutical and Vaccine Science & Technology at Elanco Animal Health (formerly a division of Eli Lilly & Company). He has extensive experience in purification process development on mammalian cell culture and microbial fermentation products in addition to chemically synthesized therapeutic peptides. He also provides technical oversight for development of biopharmaceutical manufacturing processes at third-party organizations on behalf of Elanco. Dr. Klotz joined Eli Lilly in 2000, transferred to Elanco Animal Health in 2009, and remained with Elanco through the spinout from Eli Lilly in 2019. His previous career positions include Research Manager, Department of Protein Chemistry, Novo Nordisk Biotech, Inc. and Assistant Professor, Department of Biochemistry, Louisiana State University.
Dr. Klotz received a B.A. in Biology from Rice University, Houston, Texas and a Ph.D. in Biological Oceanography from the Massachusetts Institute of Technology-Woods Hole Oceanographic Institution Joint Program in Biological Oceanography. Dr. Klotz is a co-inventor on nine U.S. patents, six patent families under prosecution in Europe, and co-author of thirty peer-reviewed publications encompassing protein chemistry, purification, structure-function relationships, and enzymology. Dr. Klotz was the lead CM&C development scientist for Elanco’s successful FDA-CVM and EMA marketing approval application for Imrestor™ (PEG-bovine GCSF).